Omarigliptin (MK-3102) [1226781-44-7]

TERT-BUTYL ((2R,3S)-2-(2,5-DIFLUOROPHENYL)-5-OXOTETRAHYDRO-2H-PYRAN-3-YL)CARBAMATE 951127-25-6
2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole benzenesulfonate 1280210-80-1

Omarigliptin (MK-3102) is an oral hypoglycemic agent of super long-lasting dipeptidyl peptidase-4 (DPP-4) developed by Merck & Co., USA. It is administered orally once a week, being able to produce sustained DPP-4 inhibition with a new mechanism of lowering blood sugar. Meanwhile, it does not increase body weight and not cause hypoglycemia and edema. Its mechanism of action is through inhibiting the degrading of the in vivo dipeptidyl peptidase-4 (DPP-4) on the GLP-1, prolonging the action time of glucagon-like peptide-1 (GLP-1), thereby increasing the blood concentration of the endogenous GLP-1 and GIP, and ultimately improving blood glucose control.

Omarigliptin (MK-3102) [1226781-44-7] Images